Navigation Links
Researchers use novel nanoparticle vaccine to cure type 1 diabetes in mice
Date:4/8/2010

NEW YORK, April 8, 2010 -- Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

The study, conducted at the University of Calgary in Alberta, Canada, was published today in the online edition of the scientific journal Immunity.

The research was led by Dr. Pere Santamaria from the Julia McFarlane Diabetes Researchers Center at the University of Calgary, Alberta. The researchers were looking to specifically stop the autoimmune response that causes type 1 diabetes without damaging the immune cells that provide protection against infections what is called an "antigen-specific" immunotherapy. Type 1 diabetes is caused when certain white blood cells (called T cells) mistakenly attack and destroy the insulin-producing beta cells in the pancreas.

Antigen-specific immunotherapies, like Dr. Santamaria's work on nanovaccines, are a priority within JDRF's Immune Therapies program.

"Essentially there is an internal tug-of-war between aggressive T-cells that want to cause the disease and weaker T cells that want to stop it from occurring," said Dr. Santamaria, who is a JDRF Scholar a research award to academic scientists taking innovative and creative approaches to better treating and curing type 1 diabetes and its complications.

The researchers developed a unique vaccine comprised of nanoparticles, which are thousands of times smaller than the size of a cell. These nanoparticles are coated with protein fragments peptides specific to type 1 diabetes that are bound to molecules (MHC molecules) that play a critical role in presenting peptides to T cells. The nanoparticle vaccine worked by expanding the number of peptide-specific regulatory T cells that suppressed the aggressive immune attack that destroys beta cells. The expanded peptide-specific regulatory cells shut down the autoimmune attack by preventing aggressive autoimmune cells from being stimulated by either the peptide contained in the vaccine or by any other type 1 diabetes autoantigen presented simultaneously on the same antigen presenting cell.

The research also provided an important insight into the ability to translate these findings in mice into therapeutics for people with diabetes: nanoparticles that contained human diabetes-related molecules were able to restore normal blood sugar levels in a humanized mouse model of diabetes.

According to Teodora Staeva, Ph.D., JDRF Program Director of Immune Therapies, a key finding from the Alberta study is that only the immune cells specifically focused on aggressively destroying beta cells (or, alternatively, regulating these cells) responded to the antigen-specific nanoparticle vaccine. That means the treatment did not compromise the rest of the immune system a key consideration for the treatment to be safe and effective in an otherwise healthy person with type 1 diabetes. "The potential that nanoparticle vaccine therapy holds in reversing the immune attack without generally suppressing the immune system is significant," said Dr. Staeva. "Dr. Santamaria's research has provided both insight into pathways for developing new immunotherapies and proof-of-concept of a specific therapy that exploits these pathways for preventing and reversing type 1 diabetes."

Dr. Santamaria noted that the study had implications for other autoimmune diseases beyond type 1 diabetes. "If the paradigm on which this nanovaccine is based holds true in other chronic autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and others, nanovaccines might find general applicability in autoimmunity," he said.

The nanoparticle vaccine technology used in the study has been licensed by Parvus Therapeutics, Inc., a biotechnology company arising from the University Technology International LP, the technology transfer and commercialization center for the University of Calgary. Parvus Therapeutics is focused on the development and commercialization of the nanotechnology-based therapeutic platform for the potential treatment of type 1 diabetes.


'/>"/>

Contact: Joana Casas
mcasas@jdrf.org
212-479-7560
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by ... Global Forecast to 2022", published by MarketsandMarkets, the market is expected to be ... 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:7/14/2017)... ... July 14, 2017 , ... Sonic ... Sonic Manufacturing Technologies has installed a solar system on its roof top. “We ... the President of Sonic, Kenneth Raab stated. The company’s proud history of social ...
(Date:7/14/2017)... ... July 14, 2017 , ... Diagenode ... of proteins to clean peptides for mass spectrometry (MS) analysis combining the PreOmics ... PreOmics iST Kit is based on proprietary technology that contains optimized buffer systems ...
(Date:7/13/2017)... ... July 13, 2017 , ... In’Tech Medical SAS ( http://www.intech-medical.com ... the completion of a major transaction with Eurazeo PME. The reputable French private ... alliance fuels In’Tech Medical’s service offerings while leveraging the company’s manufacturing expertise and ...
(Date:7/13/2017)... PA (PRWEB) , ... July 13, 2017 , ... ... business acceleration programs at Philadelphia’s University City Science Center, Christopher Laing, MRCVS, Ph.D. ... zone in Austin, Texas. Dr. Laing will become the first Executive Director ...
Breaking Biology Technology: